Anatara Lifesciences Ltd

ANR

AU000000ANR0

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 03:36:07 24/05/2024 BST			5-day change	1st Jan Change
0.044 ^AUD	0.00%		+12.82%	+100.00%

05-01	Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%	MT
04-09	Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial	MT

Anatara Lifesciences Limited Announces Cessation of Paul Adam Schober as Director

September 26, 2016 at 02:38 am

Anatara Lifesciences Limited announced that Paul Adam Schober, ceased to be director of the company, effective 23 September 2016.

Latest news about Anatara Lifesciences Ltd

Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%	05-01	MT
Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial	04-09	MT
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Anatara Lifesciences Raised Nealy AU$960,000 Via Entitlement Offer	12-08	MT
Anatara Lifesciences Ltd Announces Board Changes	01/10/23	CI
Anatara Lifesciences to Proceed to Stage II of IBS Drug Trial	28/09/23	MT
Anatara Lifesciences Finalizes Patients for Irritable Bowel Syndrome Clinical Trial Stage One	31/08/23	MT
Anatara Lifesciences Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	24/08/23	CI
Anatara Lifesciences Receives R&D Tax Rebate; Shares Up 3%	14/08/23	MT
Anatara Lifesciences Ltd Announces Registered Office Change	20/04/23	CI
Anatara Lifesciences Provides Update on the Gastrointestinal Reprogramming(Garp) Trial for IBS	09/03/23	CI
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	23/02/23	CI
Anatara Lifesciences Ltd Announces board Changes	06/12/22	CI
Anatara Lifesciences Raising Funds for Patient Trial, Future Project Acquisitions	21/10/22	MT
Anatara Lifesciences Receives More than $310,000 R&D Tax Rebate	05/10/22	MT
CSIRO Halts Psychological Functioning Trial for Dietary Supplement	03/10/22	MT
Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial	02/10/22	CI
Anatara Lifesciences Limited Reports Earnings Results for the Full Year Ended June 30, 2022	29/08/22	CI
Anatara Lifesciences Modifies Protocol for Upccoming Gastrointestinal Disease Trial	11/08/22	MT
Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer	22/06/22	CI
Anatara Lifesciences Limited Announces to Provide an Update on the Progress of Clinical Trials in Irritable Bowel Syndrome and Psychological Functioning	22/06/22	CI
Anatara Lifesciences Expands Criteria for Irritable Bowel Trial	20/05/22	MT
Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype	20/05/22	CI
Anatara Lifesciences CEO to Step Down	05/05/22	MT
Anatara Lifesciences Limited Announces Chief Executive Officer Changes	05/05/22	CI

Chart Anatara Lifesciences Ltd

Duration

Period

More charts

Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is engaged in developing evidence-based solutions for gastrointestinal diseases in humans and animals. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ANATARA LIFESCIENCES LTD	+100.00%	5.58M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B